Chronocort®

WITHDRAWN · PHASE3 · Congenital Adrenal Hyperplasia

Protocol re-design required following EU Phase III results

Scientific benefit, asset-specific safety, ownership and licensing: Unknown without reviewed evidence.

Detailed evidence is available in the local Pro plan simulation.